Therma Bright updates on communications with FDA on its AcuVid COVID-19 Rapid Antigen Saliva Test

Therma Bright Inc (TSX-V:THRM) (OTCMKTS:TBRIF) (FRA:JNX) CEO Rob Fia tells Proactive the medical device technology continues to “monitor and interact” with the FDA as necessary regarding its “active submission” for its AcuVid Covid-19 Rapid Antigen Saliva Test.

Fia says while waiting on the FDA decision, the Toronto, Ontario-based company has ordered sufficient materials and components to manufacture the first batch of AcuVid tests in the US. At the same time, Therma Bright is securing multiple manufacturing sites in different countries to be able to meet the anticipated demand for our test in the US and elsewhere.


Recent Posts

News Releases